Tags : AD

Regulatory

Eli Lilly’s Olumiant (baricitinib) Receives FDA’s Fast Track Designation for

Shots: The FDA’s designation is based on P-II study results assessing Baricitinib in patients with SLE, presented at European Congress of Rheumatology 2018 Lilly is also evaluating baricitinib’s two doses in P-III SLE trials and for moderate-to -severe atopic dermatitis, with its expected results in H1’19 Olumiant (baricitinib) 2mg is an inhibitor of janus kinase, further blocking […]Read More